.August 28, 2024 07:00:05 AM

Inozyme Pharma, Inc. (NASDAQ:INZY) and Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) join MDxHealth SA (Euronext:MDXH) in showing negative Return on Invested Capital (ROIC) figures, indicating inefficiency in generating profits from investments. Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) stands out with an exceptionally high ROIC of 599.72% and an ROIC/WACC ratio of 75.52, showcasing highly efficient use of capital. The comparison of these companies reveals varying degrees of financial efficiency and growth potential within the sector, with Eledon Pharmaceuticals leading the pack in terms of generating returns on invested capital relative to its cost of capital.